AZTR receives NYSE delisting warning over equity requirement
Jack W. Callicutt, Chief Financial Officer of Galectin Therapeutics Inc (NASDAQ:GALT), a company whose stock has surged over 316% year-to-date according to InvestingPro data, sold 8,706 shares of common stock on September 12, 2025. The shares were sold at prices ranging from $6.33 to $6.68, for a total value of $56,053.
On the same day, Callicutt also exercised options to acquire 8,706 shares of Galectin Therapeutics at an exercise price of $1.37, for a total value of $11927. These options stemmed from a stock option grant and were fully vested.
Following the sale, Callicutt directly owns 7,614 shares of Galectin Therapeutics.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on April 17, 2025.
In other recent news, Galectin Therapeutics has secured a $10 million unsecured line of credit from its Board Chairman, Richard E. Uihlein. This credit facility allows the company to borrow funds at its discretion until April 30, 2026, with the principal and interest due by September 30, 2026. The interest rate is set at the Applicable Federal Rate for short-term loans, currently 4.05%, plus an additional 2%. In analyst updates, H.C. Wainwright has initiated coverage of Galectin Therapeutics with a buy rating. The firm has set a price target of $6.00, highlighting the company’s lead asset, belapectin, as the only therapy currently in development for MASH cirrhosis and portal hypertension. Belapectin targets galectin-3, a protein involved in various cellular processes. These developments are part of the company’s ongoing efforts to advance its therapeutic offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.